Opendata, web and dolomites

OPTIMIsE

Commercial feasibility of the Novio-PlainGel: a novel synthetic, reversible thermosensitive, biomimetic hydrogel for organoid-based precision medicine

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 OPTIMIsE project word cloud

Explore the words cloud of the OPTIMIsE project. It provides you a very rough idea of what is the project "OPTIMIsE" about.

transmission    bv    unmet    models    profitability    million    platform    sarcoma    later    matrix    hydrogel    natural    excellent    pathogen    pancreatic    vivo    optimal    organoid    bio    material    extracellular    organoids    company    market    standard    precision    hampered    small    thermosensitive    stem    exponentially    recovery    clinics    up    ex    revenues    ease    proof    medicine    immunologic    disease    feasibility    validation    uniquely    sensitive    initially    biomaterial    drug    cultured    diagnostic    clinical    batch    innovative    stage    perform    culture    basement    risk    3d    reversible    extract    personalised    pic    cell    matrigel    mouse    noviocell    downstream    performance    culturing    membrane    thermo    cancer    tissue    possibilities    commercial    hydrogels    combination    polyisocyanopeptide    mini    sub    builds    cumulative    variability    matrices    spur    biomechanics    optimise    proprietary    gt    organs    synthetic    introduction    biotechnology   

Project "OPTIMIsE" data sheet

The following table provides information about the project.

Coordinator
NOVIOCELL BV 

Organization address
address: KLOOSTERSTRAAT 9 RE1131
city: OSS
postcode: 5349 AB
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Project website http://www.noviocell.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2016
 Duration (year-month-day) from 2016-06-01   to  2016-09-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    NOVIOCELL BV NL (OSS) coordinator 50˙000.00

Map

 Project objective

Noviocell BV is a highly innovative biotechnology company and builds upon its proprietary polyisocyanopeptide (PIC) hydrogel. This is a novel synthetic, reversible thermosensitive hydrogel for 3D cell culturing. PIC hydrogels uniquely perform like a natural biomaterial, while being fully reversible thermo-sensitive, which allows for ease of cell/tissue recovery and easy downstream processing after culturing. In addition, PIC hydrogel has a unique combination of bio-functionality and biomechanics that makes them excellent matrices for 3D stem cell culture. During OPTIMIsE, Noviocell BV will investigate the technical and commercial feasibility of using the PIC hydrogel as a platform for the clinical use of organoids (mini organs ex vivo). The use of organoids in a clinical set-up has the potential to open up unique possibilities for precision medicine, as it can facilitate organoid-based drug testing and provide disease specific models. However, their clinical use is currently hampered because of batch-to-batch variability, sub-optimal extracellular matrix, small scale production and the risk of immunologic response and pathogen transmission (as they cultured in Matrigel which a basement membrane extract from mouse sarcoma). The PIC hydrogel, due to its unique characteristic, can address these unmet needs and facilitate the use of organoids for personalised medicine. The validation of PIC hydrogel initially as the best hydrogel for growing organoids (using pancreatic organoids as a proof of concept) and at a later stage as a diagnostic platform in clinics will spur the profitability and growth performance of Noviocell BV. It is estimated that within 5 years after market introduction of the PIC hydrogel, Noviocell BV will have cumulative revenues of >€40,7 million (only in the pancreatic cancer market). These revenues will exponentially increase when the PIC hydrogel will become the standard material for growing organoids.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "OPTIMISE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "OPTIMISE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

CLOSER (2019)

Childhood Leukemia: Overcoming distance between South America and Europe Regions

Read More  

PREFERABLE (2019)

Project on Exercise for Fatigue Eradication in Advanced Breast cancer to improve quality of life

Read More  

GACD (2019)

Global Alliance for Chronic Diseases Secretariat

Read More